Mundipharma Satisfies Appetite For Piece Of $4.5bn Pegfilgrastim Pie With Cinfa Biotech Buy
Mundipharma widens its biosimilar portfolio by acquiring Cinfa Biotech, and its soon-to-be-launched pegfilgrastim biosimilar.
You may also be interested in...
Mylan's Kokino spoke with Scrip about what he called the successful launch of the company's first biosimilar in the US, a version of Amgen's Neulasta, the state of the US biosimilar market and resetting expectations.
With the impending European launch of Humira biosimilar adalimumab in October, Scrip talks to some of those in the region that have experience in launching commercially successful biosimilars about uptake, discounts and payer attitudes.
Mundipharma has acquired a next-generation chemotherapy agent from German biotech CellAct to further expand its oncology portfolio.